Hazlett Burt & Watson Inc. Has $55,000 Position in Zimmer Biomet Holdings, Inc. $ZBH

Hazlett Burt & Watson Inc. lessened its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 20.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 605 shares of the medical equipment provider’s stock after selling 156 shares during the period. Hazlett Burt & Watson Inc.’s holdings in Zimmer Biomet were worth $55,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. OneDigital Investment Advisors LLC bought a new position in shares of Zimmer Biomet during the 1st quarter worth about $269,000. Truist Financial Corp boosted its position in Zimmer Biomet by 34.4% in the second quarter. Truist Financial Corp now owns 26,819 shares of the medical equipment provider’s stock valued at $2,446,000 after buying an additional 6,867 shares in the last quarter. State of Alaska Department of Revenue lifted its position in shares of Zimmer Biomet by 89.8% during the second quarter. State of Alaska Department of Revenue now owns 44,261 shares of the medical equipment provider’s stock worth $4,036,000 after purchasing an additional 20,945 shares in the last quarter. Bridge Creek Capital Management LLC lifted its position in shares of Zimmer Biomet by 12.3% during the second quarter. Bridge Creek Capital Management LLC now owns 30,133 shares of the medical equipment provider’s stock worth $2,748,000 after purchasing an additional 3,297 shares in the last quarter. Finally, Thomasville National Bank lifted its position in shares of Zimmer Biomet by 3.0% during the second quarter. Thomasville National Bank now owns 105,805 shares of the medical equipment provider’s stock worth $9,650,000 after purchasing an additional 3,053 shares in the last quarter. Institutional investors own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

ZBH has been the subject of a number of recent research reports. Weiss Ratings reissued a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Wednesday, October 8th. Roth Capital reaffirmed a “buy” rating on shares of Zimmer Biomet in a research report on Thursday, August 7th. Redburn Partners set a $130.00 target price on shares of Zimmer Biomet in a research report on Thursday, September 18th. Rothschild & Co Redburn initiated coverage on shares of Zimmer Biomet in a research note on Thursday, September 18th. They issued a “buy” rating and a $130.00 price target for the company. Finally, BTIG Research raised their target price on shares of Zimmer Biomet from $118.00 to $122.00 and gave the stock a “buy” rating in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, eight have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $113.16.

Insider Activity at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of Zimmer Biomet stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $104.15, for a total transaction of $156,225.00. Following the transaction, the senior vice president directly owned 6,833 shares of the company’s stock, valued at approximately $711,656.95. This trade represents a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.70% of the company’s stock.

Zimmer Biomet Trading Up 0.4%

Shares of ZBH opened at $95.13 on Tuesday. The firm’s 50 day simple moving average is $101.36 and its 200 day simple moving average is $98.03. The company has a market capitalization of $18.85 billion, a P/E ratio of 23.15, a P/E/G ratio of 2.18 and a beta of 0.67. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96. Zimmer Biomet Holdings, Inc. has a 1-year low of $89.22 and a 1-year high of $114.72.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating analysts’ consensus estimates of $1.98 by $0.09. The business had revenue of $2.08 billion for the quarter, compared to the consensus estimate of $2.06 billion. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. Zimmer Biomet’s quarterly revenue was up 7.0% on a year-over-year basis. During the same period last year, the firm posted $2.01 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is 23.36%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.